期刊文献+

354例T1期乳腺癌患者的淋巴结转移和预后分析 被引量:7

Lymph node metastasis and prognostic analysis of 354 cases of T1 breast cancer
原文传递
导出
摘要 目的分析T1期乳腺癌患者的淋巴结转移和预后的特点。方法收集2007年3月至2011年9月间354例T1期乳腺癌患者的临床资料,分析T1期乳腺癌患者的临床病理特征与淋巴结转移的关系和预后特点。结果354例T1期乳腺癌患者中,淋巴结转移105例,淋巴结转移率为29.7%。其中淋巴结转移1~3枚者73例(69.5%),≥4枚者32例(30.5%)。T1a期患者的淋巴结转移率为8.3%,T1b期患者的淋巴结转移率为39.7%,T1C期患者的淋巴结转移率为30.4%(P=0.005)。两两比较显示,T1a期与T1b期和T1c期乳腺癌患者的淋巴结转移率差异有统计学意义(P=0.001,P=0.006),T1b期和T1C期乳腺癌患者的淋巴结转移率差异无统计学意义(P=0.171)。354例T1期乳腺癌患者中,92例患者有脉管瘤栓,其淋巴结转移率为71.7%;262例患者无脉管瘤栓,其淋巴结转移率为14.9%(P〈0.001)。中位随访时间49个月,12例患者复发,3例死亡,其中1例死于脑血管意外。全组患者的4年无病生存率为96.6%,4年生存率为99.2%。结论T1期乳腺癌患者脉管瘤栓和肿瘤大小与淋巴结转移率有关,T1a期乳腺癌患者的淋巴结转移率较低,T1b期和T1c期乳腺癌患者的淋巴结转移率相对较高。与无脉管瘤栓患者比较,有脉管瘤栓的T1期乳腺癌患者淋巴结转移率更高。T1期乳腺癌患者的预后较好。 Objective To analyze the characteristics of lymph node metastasis and prognosis in patients with T1 breast cancer. Methods The clinicopathologieal data of 354 patients with T1 breast cancer after standard treatment from March 2007 to September 2011 were collected to analyze the relationship between the clinical characteristics of T1 breast cancer, lymph node metastasis and prognostic features. Results In the 354 patients with T1 breast cancer, 105 patients (29.7%) had lymph node metastasis, among them 73 cases (69.5%) had 1-3 lymph node metastasis, and 32 cases (30.5%) had more than 4 lymph node metastasis. The lymph node metastasis rate was 8.3% in Tla patients, 39.7% in Tlb patients, and 30.4% in Tlc cases ( P = 0. 005 ). Pairwise comparison showed that the difference of lymph node metastasis rate between Tla,Tlb and Tlc patients was statistically significant ( P = 0. 001 and P = 0. 006, respectively). The difference of lymph node metastasis rates in Tlb and Tlc patients was statistically insignificant (P = 0.171 ). In the 354 patients of T1 breast cancer, 92 patients had vascular tumor thrombi and their lymph node metastasis rate was 71.7% , while the lymph node metastasis rate in 262 patients without vascular tumor thrombus was 14.9% ( P 〈 0. 001 ). The median follow-up was 49 months ( range 27- 81 months). 12 patients developed recurrence, and 3 patients died, one of them died of cerebrovaseular accident. The 4-year disease-free survival for all patients was 96.6% , and the 4-year overall survival rate was 99.2%. Conclusions There is a correlation between vascular tumor thrombus, tumor size and lymph node metastasis rate. The lymph node metastasis rate is lower in Tla patients and relatively higher in T1b/c patients. Compared with patients without vascular tumor thrombus, the T1 breast cancer patients with vascular tumor thrombi have a higher lymph node metastasis rate. Generally speaking, there is a still good prognosis in patients with T1 breast cancer.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2014年第5期382-385,共4页 Chinese Journal of Oncology
关键词 乳腺肿瘤 肿瘤分期 淋巴转移 预后 Breast neoplasms Neoplasm staging Lymphatic metastasis Prognosis
  • 相关文献

参考文献19

  • 1Ichizawa N, Fnkutomi T, Iwamoto E, et al. Long-term results of T1a, T1b and T1c invasive breast cancinomas in Japanese women : validation of the UICC T1 subgroup classification[J]. Jpn J Clin Oncol, 2002, 32(3) :108-109.
  • 2Leimer SP, Swern AS, Weinberger D, et al. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,bNOMO) [J]. Cancer,1995, 76(11):2266-2274.
  • 3Fisher B, Dignam J, Tan-Chiu E, et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes[J]. J Natl Cancer Inst, 2001,93(2) :112- 120.
  • 4Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 em or smaller[J]. J Clin Oncol, 2009, 27(34) :5700-5706.
  • 5Therianlt RL, Litton JK, Mittendorf EA, et al. Age and survival estimates in patients who have node-negative T1 ab breast cancer by breast cancer subtype[J]. Clin Breast Cancer, 2011, 11 (5) : 325-331.
  • 6Hanrahan EO, Gonzalez-Angnlo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma [ J ]. J Clin Oncol, 2007, 25 (31) : 4952-4960.
  • 7Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer [ J ]. Breast Cancer Res Treat, 1998, 52 ( 1-3 ) :227-237.
  • 8Carter CL, Allen C, Hanson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases [ J ].Cancer, 1989, 63 (1) : 181-187.
  • 9Chia SK, Speers CH, Bryce CJ, et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies [J]. J Clin Oncol, 2004, 22 (9) : 1630-1637.
  • 10Port ER, Tan LK, Borgen PI, et al. Incidence of axillary lymph node metastases in T1 a and T1 b breast carcinoma [ J ]. Ann Surg Oncol, 1998, 5(1) : 23-27.

同被引文献46

  • 1尹益民,任晓萍,潘文倩,艾红.高频超声及钼靶X线检查在乳腺癌诊断中的应用价值[J].西安交通大学学报(医学版),2012,33(5):572-575. 被引量:79
  • 2朱亚东.乳腺癌术后无瘤生存率的影响因素及腋窝淋巴结检测数目的临床意义[J].实用癌症杂志,2014,29(2):222-225. 被引量:8
  • 3王艳滨,张晖,高文,张琳,严昆,尹珊珊,陈敏华.超声判断乳腺癌患者腋淋巴结转移的多因素分析[J].中华肿瘤杂志,2006,28(1):65-69. 被引量:15
  • 4中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2007版)[J].中国癌症杂志,2007,17(5):410-428. 被引量:232
  • 5Du Y,J Meng, Y Huang, et al. Guanine nucleotide-bindingprotein subunit beta-2-like 1,a new Annexin A7 interacting pro-tein[J]. Biochem Biophys Res Commun, 2014,445(1): 58-63.
  • 6Jin Y, Wang S, Chen W, et al, Annexin A7 suppresses lymphnode metastasis of hepatocarcinoma cells in a mouse model[J].BMC Cancer, 2013(13): 522.
  • 7Milioli H H, Santos Sousa K, Kaviski R, et al. Comparative pro- teomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion [ J ]. Cancer Genomics Pro- teomics, 2015,12(2) :89 - 102.
  • 8Kassouf W, Agarwal P K, Herr H W, et al. Lymph node density is superior to TNM nodalstatus in predicting disease-specific sur- vival after radical cystectomy for bladder cancer : analysis of pooled data from MDACC and MSKCC[J]. J Clin Oncol, 2008,26(1) : 121 -6.
  • 9Yamashita K, Ooki A, Sakuramoto S, et al. Lymph node metasta- sis density (ND)-factor association with malignant degree and ND40 as "non-curative factor" in gastric cancer[ J]. Anticancer Res, 2008,28(1B) :435 -41.
  • 10Yamashita K, Katagiri H, Ishii K, et al. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer[J]. Ann Surg Oncol, 2009,16(5) :1231 -40. Ooki A, Yamashita K, Kobayashi N, et al. Lymph node metasta- sis density and growth pattern as independent.

引证文献7

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部